



COPY OF PAPERS
ORIGINALLY FILED

Patent
266/254

#70
6-11-02
R2.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

RON, Yacov et al.

Serial No.: 09/830,176

Filed: April 23, 2001

For: A MYELOID PRECURSOR CELL
USEFUL FOR GENE THERAPY AND FOR
MODULATION OF IMMUNE RESPONSES

Group Art Unit: 1632

Examiner: not yet assigned

RECEIVED

JUN 0 6 2002

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In accordance with 37 CFR §§ 1.97 and 1.98, the items identified in this Information Disclosure Statement ("IDS") are brought to the attention of the Office. The items are listed on the attached form PTO-1449 and copies are enclosed for the convenience of the Examiner.

The items identified in this IDS may or may not be "material" pursuant to 37 CFR § 1.56. The submission thereof by Applicant is not to be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as "prior art" under 35 USC § 102 with respect to this invention unless specifically designated by Applicant as such.

LA-235878.1

CERTIFICATE OF MAILING
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

May 14, 2002
Date of Deposit

Rachel Marquez
Name of Person Mailing Paper

Signature of Person Mailing Paper



COPY OF PAPERS
ORIGINALLY FILED

Patent
266/254

INFORMATION DISCLOSURE STATEMENT FILING PROVISION:

This IDS is believed to be timely in that it is being submitted under 37 CFR § 1.97(b), that is (1) within three months of the filing date of the application, which is not a continued prosecution application filed under § 1.53(d); or (2) within three months of entry of the national stage as set forth in 37 CFR § 1.491; or (3) before the mailing of a first Office action on the merits; or (4) before the mailing of a first Office action after filing a request for continued examination under § 1.114. Thus, no fee is required.

However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and charge the fee due under 37 CFR § 1.17(p) or any fees required by this filing to Lyon & Lyon's Deposit Account No. 12-2475.

Respectfully submitted,
LYON & LYON LLP

Dated: 5/14/02

By: Sandra S. Fujiyama
Sandra S. Fujiyama
Reg. No. 46,713



22249

PATENT TRADEMARK OFFICE

LYON & LYON LLP
633 W. Fifth Street, Suite 4700
Los Angeles, CA 90071
Phone: (213) 489-1600
Fax: (213) 955-0440